Clinical trials: Female Breast Neoplasms
Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
- Trial name
- NCT05544929
- Testing
- KFA115, pembrolizumab
- Where
- 18 sites in United States, Canada and 10 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Evaluation of Beauty Care Before Chemotherapy in Women With Breast Cancer
Evaluation of beauty care in women receiving adjuvant chemotherapy for breast cancer
- Trial name
- BEAUTY (NCT01459003)
- Testing
- beauty care
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Neoplasms, Breast
Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China
Local study in China and Hong Kong to evaluate safety and efficacy in lapatinib + capecitabine in women with Human epidermal growth factor receptor 2 (HER2) positive advanced or metastatic breast cancer.
- Trial name
- NCT00508274
- Testing
- lapatinib, capecitabine
- Where
- 11 sites in China, Hong Kong
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Ovarian Cancer
Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study
This Pilot Study is to investigate the tear proteins in a multitude of cancer types and indulge in biomarker discovery to manufacture simple, accurate, and novel tear-based diagnostic tests.
- Conditions
- Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- NCT05223218
- Testing
- Schirmer strip, a Class I Medical Device typically used to test for dry eye.
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Namida Lab
Breast Cancer
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00003418
- Testing
- exemestane, tamoxifen citrate
- Where
- 3 sites in Belgium, France and 1 more
- Volunteers
- 4,400 people
- Sponsor
- International Collaborative Cancer Group
Breast Cancer Female
Breast Cancer Recurrence Risk Counseling
The number of breast cancer survivors is growing. Women with a personal history of breast cancer worry about their risk of getting cancer again.
- Trial name
- BRIM3 (NCT03339518)
- Testing
- BRIM3 educational intervention, Wait List
- Where
- 2 sites in United States
- Volunteers
- 173 people
- Sponsor
- West Virginia University
Breast Neoplasms
Mobile Health (mHealth) Black Women With Breast Cancer
This research study will test whether a series of video clips with breast cancer information improves knowledge of breast cancer, breast cancer treatment and living with breast cancer.
- Trial name
- NCT02463474
- Testing
- mHealth Intervention
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Breast Cancer
Bexarotene in Preventing Breast Cancer in Women at Genetic Risk
RATIONALE: Chemoprevention therapy uses certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether bexarotene is effective in preventing breast cancer.
- Trial name
- NCT00055991
- Testing
- bexarotene
- Where
- 4 sites in United States
- Volunteers
- 87 people
- Sponsor
- Baylor Breast Care Center
Breast Cancer
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer
The purpose of the study was to evaluate the safety and efficacy of a reduced ribociclib starting dose of 400 mg in combination with a non-steroidal aromatase inhibitor (NSAI) (letrozole or anastrozole) for the treatment of pre…
- Trial name
- AMALEE (NCT03822468)
- Testing
- Ribociclib, Anastrozole, Letrozole
- Where
- 89 sites in United States, Argentina and 21 more
- Volunteers
- 376 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Letrozole After Tamoxifen in Treating Women With Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen.
- Trial name
- NCT00003140
- Testing
- letrozole
- Where
- 57 sites in Canada, United Kingdom
- Volunteers
- 5,187 people
- Sponsor
- NCIC Clinical Trials Group
Estrogen Receptor Positive, Invasive Breast Carcinoma
MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer
This phase I trial studies the side effects and the best dose of MK 2206 (Akt inhibitor MK2206) when given with anastrozole, fulvestrant, or anastrozole and fulvestrant in treating postmenopausal women with breast cancer that has…
- Conditions
- Estrogen Receptor Positive, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT01344031
- Testing
- Akt Inhibitor MK2206, Anastrozole, Fulvestrant
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
This phase II trial studies how well pembrolizumab works in treating participants with cancer that has spread to other places in the body, has come back or has spread to nearby tissues or lymph nodes.
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03428802
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Rutgers, The State University of New Jersey
Breast Cancer Female
Effects of Ketogenic Diet in Overweight and Obese Women With Breast Cancer
Breast cancer is the most common cancer type among women in Turkey and the world. Chemotherapy, surgery, radiotherapy, immunotherapy and hormone therapy are used in the treatment.
- Trial name
- NCT05234502
- Testing
- Adequate and balanced healthy diet program (CHO: 45-60%, protein:10-20%, fat:20-35%), Ketogenic diet program (CHO: 6%, protein:19%, fat:75%)
- Volunteers
- 56 people
- Sponsor
- Necmettin Erbakan University
Communication, Message Perception
Messages That Motivate: Communicating Alcohol-Related Breast Cancer Risk to Young Adult Women
This is an online cross-sectional experimental survey study examining two cancer communication questions: 1) What features of social media messages communicating the breast cancer risks from alcohol consumption will motivate…
- Conditions
- Communication, Message Perception, Alcohol, Cancer Prevention
- Trial name
- MEMO (NCT07802054)
- Testing
- Risk Message, Efficacy Message, Industry Deception
- Where
- United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Neoplasm Female, Breast Cancer
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
The goal of this protocol is to evaluate the safety and efficacy of an alternative systemic combination approach that omits or delays the use of chemotherapy in metastatic disease, while improving efficacy and durability of…
- Conditions
- Breast Neoplasm Female, Breast Cancer, Breast Carcinoma, Breast Tumor
- Trial name
- NCT03650894
- Testing
- Nivolumab, Ipilimumab, Bicalutamide
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Providence Health & Services
Breast Neoplasms
Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
The purpose of this study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal Women with estrogen receptor positive (ER+), human…
- Trial name
- NCT02374099
- Testing
- CC-486, Fulvestrant
- Where
- 35 sites in United States, Belgium and 4 more
- Volunteers
- 97 people
- Sponsor
- Celgene
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer
This phase II trial studies how well docetaxel or paclitaxel work in reducing chemotherapy-induced peripheral neuropathy in African American patients with stages I-III breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04001829
- Testing
- Docetaxel, Paclitaxel, Quality-of-Life Assessment
- Where
- 482 sites in United States
- Volunteers
- 249 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Breast Cancer, Osteoporosis
Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial
RATIONALE: Learning about the effect of exemestane and anastrozole on bone mineral density in postmenopausal women with primary breast cancer may help plan treatment, decrease the risk of broken bones, and help patients live more…
- Trial name
- NCT00354302
- Testing
- calcium carbonate, calcium citrate, cholecalciferol
- Where
- 13 sites in Canada
- Volunteers
- 497 people
- Sponsor
- NCIC Clinical Trials Group
Healthy, no Evidence of Disease
Effect of Weight Loss on Breast Density Using Digital Mammography and MRI in Women Who Are At Increased Risk For Breast Cancer
Diagnostic procedures, such as digital mammography and MRI, may help measure how weight loss affects breast density in women who are at increased risk for breast cancer.
- Trial name
- NCT01259076
- Testing
- magnetic resonance imaging, digital mammography, conventional surgery
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Northwestern University
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Cancer Prevention in Women With a BRCA Mutation
This study aims to develop a follow-up telephone-based genetic counselling (FTGC) intervention for women with a BRCA1 or BRCA2 mutation who have received genetic counseling in the past.
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Breast Cancer, Ovarian Cancer
- Trial name
- NCT02225015
- Testing
- Follow-up Telephone Genetic Counselling
- Where
- 3 sites in Canada
- Volunteers
- 300 people
- Sponsor
- Women's College Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.